ストックスクリーナーアプリを入手
8.76
0.11%
-0.010
前日終値:
$8.77
開ける：
$8.75
24時間の取引高:
1.99M
Relative Volume:
1.10
時価総額：
$548.56M
収益：
$91.06M
当期純損益:
$-503.14M
株価収益率:
-1.0441
EPS:
-8.39
ネットキャッシュフロー:
$-424.74M
1週間 パフォーマンス:
-4.16%
1か月 パフォーマンス:
-4.99%
6か月 パフォーマンス:
+23.38%
1年 パフォーマンス:
-15.61%
1日の値動き範囲:
$8.75
$8.79
1週間の範囲:
$8.74
$9.17
52週間の値動き範囲:
$4.62
$11.44
Sage Therapeutics Inc Stock (SAGE) Company Profile
名前
Sage Therapeutics Inc
セクター
電話
617-299-8380
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
SAGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
8.76 | 547.94M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-11 | 再開されました | BofA Securities | Underperform |
| 2024-11-21 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-10-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-07-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-05-29 | 開始されました | Citigroup | Sell |
| 2024-05-29 | 開始されました | Robert W. Baird | Neutral |
| 2024-04-17 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Hold |
| 2023-08-08 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | ダウングレード | Goldman | Buy → Neutral |
| 2023-08-08 | ダウングレード | Needham | Buy → Hold |
| 2023-08-07 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-08-07 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-08-07 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | ダウングレード | Stifel | Buy → Hold |
| 2023-08-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-03-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-11-01 | 開始されました | Loop Capital | Hold |
| 2022-03-31 | 開始されました | Berenberg | Hold |
| 2021-11-02 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-04-07 | 開始されました | Piper Sandler | Overweight |
| 2021-02-26 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-02-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | 再開されました | Raymond James | Mkt Perform |
| 2021-01-22 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-01-04 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-09-11 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-08-10 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-04-08 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-03-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-28 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-06 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-12-05 | 繰り返されました | Guggenheim | Buy |
| 2019-12-05 | ダウングレード | SunTrust | Buy → Hold |
| 2019-10-30 | 開始されました | H.C. Wainwright | Neutral |
| 2019-05-23 | 開始されました | Wedbush | Outperform |
| 2019-04-25 | 開始されました | Jefferies | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-10-11 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Sage Therapeutics Inc (SAGE) 最新ニュース
What drives Sage Therapeutics Inc. stock priceUnbelievable profit margins - Autocar Professional
What analysts say about Sage Therapeutics Inc. stockFree Investment Community - Autocar Professional
Sage Therapeutics (SAGE) to Release Quarterly Earnings on Wednesday - MarketBeat
Sage Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Is Sage Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Sage Therapeutics (NASDAQ:SAGE) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat
ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - 富途牛牛
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, - openPR.com
Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Marinus Pharmac, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics - The Globe and Mail
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Sage Therapeutics (NASDAQ:SAGE) Downgraded to Hold Rating by Scotiabank - MarketBeat
SAGE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Sage Therapeutics, Inc. is Fair to Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Analysts - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to “Hold” at Scotiabank - Defense World
Sage Therapeutics Announces Workforce Reductions Following Recent Acquisition Plans - geneonline.com
Postpartum Depression Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, SAGE, OLO on Behalf of Shareholders - Morningstar
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock - Nasdaq
SAGE: Scotiabank Downgrades Sage Therapeutics with Price Target Adjustment | SAGE Stock News - GuruFocus
Scotiabank Downgrades SAGE Therapeutics to Sector Perform From Sector Outperform, Adjusts Price Target to $9.20 From $12 - MarketScreener
Wealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Scotiabank Downgrades Sage Therapeutics (SAGE) - MSN
Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Analysts - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - Eastern Progress
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What Makes Sage Therapeutics (SAGE) a New Buy Stock - Yahoo Finance
Sage to lay off most staff amid Supernus buyout - BioPharma Dive
Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE - ACCESS Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Phathom Pharmaceuticals Strengthens Leadership: Sage Therapeutics Legal Head Joins GI-focused Biotech as CLO - Stock Titan
SAGE: Baird Adjusts Price Target on Sage Therapeutics | SAGE Stock News - GuruFocus
Canaccord Genuity Group Issues Positive Forecast for Sage Therapeutics (NASDAQ:SAGE) Stock Price - MarketBeat
Sage Therapeutics Inc (SAGE) 財務データ
収益
当期純利益
現金流量
EPS
3.32%
1.57%
大文字化:
|
ボリューム (24 時間):